相似文献
1
Serum and cerebrospinal fluid levels of colistin in pediatric patients.
Antimicrob Agents Chemother. 2010 Sep;54(9):3985-7. doi: 10.1128/AAC.01799-09. Epub 2010 Jun 28.
2
Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis.
Eur J Clin Microbiol Infect Dis. 2002 Mar;21(3):212-4. doi: 10.1007/s10096-001-0680-2. Epub 2002 Mar 19.
3
Penetration of colistin into cerebrospinal fluid.
Antimicrob Agents Chemother. 2009 Nov;53(11):4907-10. doi: 10.1128/AAC.00345-09. Epub 2009 Aug 24.
4
Population pharmacokinetic analysis of colistin in burn patients.
Antimicrob Agents Chemother. 2013 May;57(5):2141-6. doi: 10.1128/AAC.00271-13. Epub 2013 Feb 25.
5
Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis.
Pediatr Infect Dis J. 2009 Feb;28(2):123-7. doi: 10.1097/INF.0b013e31818a5dbd.
6
Colistin administration to pediatric and neonatal patients.
Eur J Pediatr. 2010 Jul;169(7):867-74. doi: 10.1007/s00431-009-1137-3. Epub 2010 Jan 30.
7
Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study.
Int J Infect Dis. 2020 Nov;100:497-506. doi: 10.1016/j.ijid.2020.08.010. Epub 2020 Aug 8.
8
Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.
Clin Ther. 2008 Jan;30(1):143-51. doi: 10.1016/j.clinthera.2008.01.015.
9
Use of colistin in a pediatric burn unit in Argentina.
J Burn Care Res. 2009 Jul-Aug;30(4):612-5. doi: 10.1097/BCR.0b013e3181abffb6.
10
Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome.
Basic Clin Pharmacol Toxicol. 2021 Jan;128(1):128-140. doi: 10.1111/bcpt.13482. Epub 2020 Sep 4.
引用本文的文献
1
Multi-Drug Resistant Gram-Negative Sepsis in Neonates: The Special Role of Ceftazidime/Avibactam and Ceftolozane/Tazobactam.
Medicines (Basel). 2025 Jun 26;12(3):17. doi: 10.3390/medicines12030017.
2
Factors Associated with Successful Treatment of Carbapenem-Resistant Gram-Negative Bacilli Infections Using Intravenous Colistin Sulfate in China: A Real-World Retrospective Study.
Infect Drug Resist. 2025 Apr 30;18:2175-2185. doi: 10.2147/IDR.S512403. eCollection 2025.
3
Reintroduction of Legacy Antibiotics in Neonatal Sepsis: The Special Role of Fosfomycin and Colistin.
Antibiotics (Basel). 2024 Apr 5;13(4):333. doi: 10.3390/antibiotics13040333.
4
Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.
Antibiotics (Basel). 2023 Jun 19;12(6):1072. doi: 10.3390/antibiotics12061072.
5
How to Manage Pseudomonas aeruginosa Infections.
Adv Exp Med Biol. 2022;1386:425-445. doi: 10.1007/978-3-031-08491-1_16.
6
Estimation of the Difference in Colistin Plasma Levels in Critically Ill Patients with Favorable or Unfavorable Clinical Outcomes.
Pharmaceutics. 2021 Oct 6;13(10):1630. doi: 10.3390/pharmaceutics13101630.
7
Successful Treatment With Intrathecal and Intravenous Polymyxin B-Based Combination Against MDR Meningitis in Pediatric Patient: A Case Report.
Front Pediatr. 2021 Jul 27;9:564991. doi: 10.3389/fped.2021.564991. eCollection 2021.
8
Population Pharmacokinetics and Outcomes of Critically Ill Pediatric Patients Treated with Intravenous Colistin at Higher Than Recommended Doses.
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00002-21.
9
A Clinical Study on the Use of Intraventricular Polymyxin B Supplemented by Continuous External Ventricular Drainage in the Treatment of Drug-Resistant Gram-Negative Bacilli Intracranial Infection.
Infect Drug Resist. 2020 Aug 24;13:2963-2970. doi: 10.2147/IDR.S261510. eCollection 2020.
10
Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam.
Infect Drug Resist. 2020 Jun 12;13:1763-1773. doi: 10.2147/IDR.S209264. eCollection 2020.
本文引用的文献
1
Penetration of colistin into cerebrospinal fluid.
Antimicrob Agents Chemother. 2009 Nov;53(11):4907-10. doi: 10.1128/AAC.00345-09. Epub 2009 Aug 24.
2
Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.
Antimicrob Agents Chemother. 2009 Aug;53(8):3430-6. doi: 10.1128/AAC.01361-08. Epub 2009 May 11.
3
Systemic colistin use in children without cystic fibrosis: a systematic review of the literature.
Int J Antimicrob Agents. 2009 Jun;33(6):503.e1-503.e13. doi: 10.1016/j.ijantimicag.2008.10.021. Epub 2009 Jan 24.
4
Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS.
J Pharm Biomed Anal. 2009 Apr 5;49(3):760-7. doi: 10.1016/j.jpba.2008.12.016. Epub 2008 Dec 24.
5
Polymyxins revisited.
Clin Microbiol Rev. 2008 Jul;21(3):449-65. doi: 10.1128/CMR.00006-08.
6
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.
Lancet Infect Dis. 2006 Sep;6(9):589-601. doi: 10.1016/S1473-3099(06)70580-1.
7
Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography.
Antimicrob Agents Chemother. 2002 Oct;46(10):3304-7. doi: 10.1128/AAC.46.10.3304-3307.2002.
8
Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis.
Eur J Clin Microbiol Infect Dis. 2002 Mar;21(3):212-4. doi: 10.1007/s10096-001-0680-2. Epub 2002 Mar 19.
9
Antimicrobial agents and the central nervous system.
Neurosurgery. 1980 Jun;6(6):691-714. doi: 10.1227/00006123-198006000-00016.
Zotero 插件